Bionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023
09 mars 2023 16h05 HE
|
Bionano Genomics
Q4 revenue was $8.2 million, which represents a 30% increase over Q4 20212022 revenue was $27.8 million, which represents a 55% increase over year end 2021Reached installed base of 240 Saphyr® systems...
Bionano Announces Two Publications from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing including the First Peer-Reviewed Publication on the Multi-Site Evaluation of OGM Against SOC
02 mars 2023 08h00 HE
|
Bionano Genomics
Peer-reviewed publication from Iqbal, et al. describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows: Concordance of OGM against...
Bionano to Report Fourth Quarter and Year End 2022 Financial Results and Host a Conference Call and Webcast March 9, 2023
01 mars 2023 08h00 HE
|
Bionano Genomics
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9th, 2023 at 4:30 p.m....
Bionano to Present at the 43rd Annual Cowen Healthcare Conference
27 févr. 2023 08h00 HE
|
Bionano Genomics
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin,...
Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies
22 févr. 2023 08h00 HE
|
Bionano Genomics
Bionano original equipment manufacturing (OEM) partner Beijing Genome Precision Technology (BGPT) obtained reagent class I registration and approval for DNA isolation and labeling kits from China's...
Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity
14 févr. 2023 16h39 HE
|
Bionano Genomics
Bionano leaders presented on the ability of optical genome mapping (OGM) to potentially replace traditional cytogenetic methods for structural variant (SV) detection and shared details of the...
Bionano Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research
09 févr. 2023 16h05 HE
|
Bionano Genomics
Bionano’s chief executive officer, chief financial officer, chief medical officer, chief operating officer and vice president of clinical and scientific affairs delivered an in-depth review of the...
Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research
02 févr. 2023 08h00 HE
|
Bionano Genomics
Over 3,000 registrants with attendees from 114 countriesAverage daily attendance of 750 in 2023 versus 565 in 202231 oral presentations delivered across four consecutive days69 scientific posters...
Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies
24 janv. 2023 08h00 HE
|
Bionano Genomics
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of...
Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
23 janv. 2023 08h01 HE
|
Bionano Genomics
Bionano Prep SP-G2 (SP-G2) kit offers higher gDNA quality, improved ease-of-use and increased DNA throughputBionano Prep Direct Label and Stain-G2 (DLS-G2) kit offers increased reagent stability and...